Pyxis Oncology, Inc. (PYXS)
$1.61
Rating:
Recommendation:
-
Symbol | PYXS |
---|---|
Price | $1.61 |
Beta | 0.000 |
Volume Avg. | 0.18M |
Market Cap | 56.507M |
Shares () | - |
52 Week Range | 1.1-9.49 |
1y Target Est | - |
DCF Unlevered | PYXS DCF -> | |
---|---|---|
DCF Levered | PYXS LDCF -> | |
ROE | -52.56% | Strong Sell |
ROA | -52.55% | Strong Sell |
Operating Margin | - | |
Debt / Equity | 18.62% | Neutral |
P/E | - | |
P/B | 0.28 | Neutral |
Latest PYXS news
About
Download (Excel)Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.